VERIPRED 20 Rx
Generic Name and Formulations:
Prednisolone (as sodium phosphate) 20mg/5mL; soln; dye- and alcohol-free; grape-flavor.
Indications for VERIPRED 20:
See literature. Individualize. Initially 5–60mg/day.
See literature. Individualize. Initially 0.14–2mg/kg/day in 3–4 divided doses.
Systemic fungal infections. Live vaccines.
May increase risk and mask signs of infection. Tuberculosis. Latent amebiasis. Strongyloides infestation. Ocular herpes simplex. Cerebral malaria. If exposed to chickenpox or measles, consider prophylaxis with immunoglobulin. Supplement with additional steroids in physiologic stress. Hypertension. Renal insufficiency. CHF. Hypothyroidism. Cirrhosis. Kaposi's sarcoma. Ulcerative colitis if perforation pending. Peptic ulcer. Diverticulitis. Intestinal anastomoses. Myasthenia gravis. Osteoporosis. Diabetes. Avoid abrupt cessation. May cause electrolyte imbalances, adrenocortical insufficiency, psychotic derangements. Use lowest effective dose. Monitor weight, growth, fluid and electrolyte balance, intraocular pressure. Elderly. Pregnancy (Cat.C). Nursing mothers.
Barbiturates, hydantoins, rifampin, ephedrine, other hepatic enzyme inducers may decrease effects. Potentiated by ketoconazole, estrogens (eg, oral contraceptives). Potentiates and potentiated by cyclosporine. Increased risk of GI effects with aspirin or other NSAIDs. Monitor oral anticoagulants. Excretion of salicylates may be increased. Caution with K+ depleting agents (eg, diuretics, amphotericin-B), digoxin, aspirin in hypoprothrombinemia. Withdraw anticholinesterases at least 24 hours before starting steroids. Adjust antidiabetic agents. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, CHF, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC